Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001533

Praziquantel

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H24N2O2
Numéro CAS:
55268-74-1
Poids moléculaire :
312.41
Numéro Beilstein :
761557
Numéro MDL:
MFCD00058531
Code UNSPSC :
41116107
ID de substance PubChem :
329831478
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

praziquantel

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

Clé InChI

FSVJFNAIGNNGKK-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Praziquantel for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

P2670000

Praziquantel, European Pharmacopoeia (EP) Reference Standard

PHR1391

Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material

1554658

Composé A apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

1554603

Praziquantel, United States Pharmacopeia (USP) Reference Standard

1554669

Composé B apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

1554670

Composé C apparenté au praziquantel, United States Pharmacopeia (USP) Reference Standard

PHR2961

(11bRS)-2-Benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, pharmaceutical secondary standard, certified reference material

PHR2962

2-(Cyclohexylcarbonyl)-2,3,6,7-tétrahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, pharmaceutical secondary standard, certified reference material

PHR2963

2-(N-Formylhexahydrohippuroyl)-1,2,3,4-tétrahydroisoquinoline-1-one, pharmaceutical secondary standard, certified reference material

Mentions de danger

H412

Conseils de prudence

P273

Classification des risques

Aquatic Chronic 3

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Michael C Jeziorski et al.
International journal for parasitology, 36(6), 625-632 (2006-03-21)
Voltage-gated calcium (Ca2+) channels provide the pathway for Ca2+ influxes that underlie Ca2+ -dependent responses in muscles, nerves and other excitable cells. They are also targets of a wide variety of drugs and toxins. Ca2+ channels are multisubunit protein complexes
Charles H King et al.
PLoS neglected tropical diseases, 5(9), e1321-e1321 (2011-09-29)
Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
Michael J Doenhoff et al.
Current opinion in infectious diseases, 21(6), 659-667 (2008-11-04)
Praziquantel (PZQ) is the only drug being used to treat human schistosomiasis on a large scale. This review focuses on current knowledge about the mechanisms of action of PZQ, prospects for PZQ resistance, possible future alternative drugs and on exhortations
Rong Liu et al.
Parasites & vectors, 4, 201-201 (2011-10-19)
Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984. Besides praziquantel, artemether and artesunate have also been used for the control of this infectious disease since late 1990s. In this article, we conducted a systematic review
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique